相关实验视频
Updated: Jul 6, 2025

04:26
Postoperative Ileus Murine Model
Published on: July 12, 2024
624
贝塔-上腺体受体在大鼠手术后内脏病中的作用
Bitel Marcin1, Sztormowska-Achranowicz Katarzyna1, Kocić Ivan2
1Department of Pharmacology, Faculty of Medicine, Medical University of Gdańsk, Dębowa Str. 23, 80-204, Gdańsk, Poland.
Naunyn-Schmiedeberg's archives of pharmacology
|December 29, 2023
概括
高剂量的兰,一种β-上腺素受体对抗剂,改善了术后结肠病的老鼠的肠机动性. 这种效应可能源于膜稳定,而不是受体阻塞.
科学领域:
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
- 手术研究的研究.
背景情况:
- 手术后的结节 (POI) 是腹部手术后的一种常见并发症,其特点是肠道运动能力受损.
- β-上腺素受体在调节胃肠功能方面发挥作用.
- 了解特定β-上腺素受体对抗剂对POI的影响对于开发治疗策略至关重要.
研究的目的:
- 在POI的小鼠模型中,研究β-上腺素受体亚型对抗剂对肠道运动的作用.
- 为了确定propranolol或选择性β-上腺抗剂是否影响腹部手术后的肠道穿行.
主要方法:
- 雄性大鼠接受了手术程序,包括皮肤切口,腹腔切口和腹腔切口与肠道操纵.
- 通过测量埃文斯蓝色染料的肠道通行量来评估肠道移动性,该染料是通过口胃管给药的.
- 小鼠接受了propranolol或选择性β1,β2,β3上腺素受体对抗剂 (metoprolol,ICI 118.551,SR58894A) 的腹腔内给药.
主要成果:
- 在手术前给予普罗普拉诺洛尔,在接受肠道操纵腹腔切除术的老鼠中显示出对染料迁移的保护作用.
- 与对照组相比,使用更高剂量的普罗巴诺洛尔 (30和45毫克/公斤) 观察到染料通路的统计学上显著增加.
- 选择性β1,β2和β3上腺体受体抗剂没有加速染料迁移,这表明propranolol的非受体介导作用.
结论:
- 在大鼠模型中,高剂量的普拉诺洛尔可以在术后阴茎的早期阶段改善肠道运动.
- 兰醇所观察到的促运动效应可能归因于其膜稳定性质,而不是特定的β-上腺素受体阻塞.
- 进一步研究兰醇的非受体介导作用可能为管理POI提供新的治疗途径.
更多相关视频
相关概念视频
Adrenergic Receptors: β Subtype
1.7K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.7K
Adrenergic Receptors: ɑ Subtype
1.5K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.5K
Adrenergic Receptors (Adrenoceptors): Classification
2.6K
Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
2.6K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
746
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
746
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
813
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
813

